Orthocell https://validator.w3.org/feed/docs/rss2.html Orthocell featured in AusBiotech Spotlight series Surgical Solutions for Peripheral Nerve Repair Dinner & Lecture Orthocell achieves first Remplir™ sales in US$75 million Canadian Market Q&A with Phil Edmondson, VP of US Commercialization Team 2026 Nerve Symposium Tendon Nerve Symposium – Perth Contact Orthocell reports continued growth and strong US momentum in March 2026 quarter Orthocell secures Remplir™ approval across U.S. Department of Defence Hospital Network Investor Presentations | March 2026 Front Page Remplir™ RWE study delivers 90% success rate Nerve Symposium – Thank You Page Nerve Symposium Remplir™ Exempt from US Pharma Tariffs Due to Medical Device Status The Armchair Analyst | What makes a surgeon adopt a product? Products Remplir™ Used in 23 Surgeries on Injured Soldiers in Ukraine Striate eIFU First Remplir™ Surgical Case Completed in U.S. Department of Defense Hospital Network  Invest Commercialisation of Remplir™ into US Market Continues to Build Momentum Practitioners February 2026 Orthocell Investor Webinar Replay   About Orthocell Appoints Second Canadian Distributor for Remplir™ Quarterly Report for period ended 31 December 2025 Orthocell Co-Founder Professor Minghao Zheng Appointed Member of the Order of Australia (AM) Ausbiz | Interview with John Van Der Wielen  Orthocell Appoints Exclusive Remplir™ Distributor for Hong Kong Orthocell Appoints First Distributor for Remplir™ in US$75m Canadian Market Global opportunity emerges as Remplir™ is used in nerve-sparing prostate cancer surgery AFR | The company repairing human bone with Kimberley pearl shells. Orthocell Strengthens Asian Growth Platform with First Commercial Sales in Hong Kong Orthocell Records Seventh Consecutive Quarter of Record Revenue at $3.2m Professor Minghao Zheng elected Fellow of the Australian Academy of Health and Medical Sciences   Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum Orthocell Announces Record Revenue of $3m for September Quarter STOCKHEAD | Orthocell flags rapid ‘hockey stick’ revenue growth in the US$1.6 billion US nerve repair market Orthocell secures global distribution rights to innovative bone regeneration technology Orthocell Submits Regulatory Application for Remplir™ into EU and UK $30.0 Million Placement to Accelerate Global Commercialisation and Advance Product Portfolio Orthocell Finalises Formal Agreement with Marine Biomedical and Secures Strategic Rights to Groundbreaking Bone Regeneration Technology, PearlBone™ Quarterly Report – period ended 30 September 2025 Remplir™ Real World Evidence study delivers compelling 81% success rate First Remplir™ Surgical Case Completed in Hong Kong First US Sales Revenue from Remplir™ Blog